Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Oncology

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    September 2024
  1. JUNG YJ, Lee S, Kang SK, Kim JY, et al
    Clinicopathological factors predicting pathological complete response to neoadjuvant anti-HER2 therapy in HER2-positive breast cancer.
    Oncology. 2024 Sep 9:1-16. doi: 10.1159/000541019.
    PubMed     Abstract available


    August 2024
  2. OYAMA Y, Kittaka N, Higuchi A, Togashi Y, et al
    Long-term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 Strategy.
    Oncology. 2024 Aug 19. doi: 10.1159/000540363.
    PubMed     Abstract available


  3. ZAVESKY L, Jandakova E, Weinberger V, Minar L, et al
    The overexpressed microRNAs miRs-182, 155, 493, 454 and U6 snRNA, and underexpressed let-7c, miR-328 and miR-451a as potential biomarkers in invasive breast cancer and their clinicopathological significance.
    Oncology. 2024 Aug 12. doi: 10.1159/000540863.
    PubMed     Abstract available


    July 2024
  4. KOVACOVA M, Hlavac V, Kozevnikovova R, Raus K, et al
    Artificial Intelligence-driven Prediction Revealed CFTR Associated With Therapy Outcome Of Breast Cancer: A Feasibility Study.
    Oncology. 2024 Jul 18. doi: 10.1159/000540395.
    PubMed     Abstract available


    February 2024
  5. ZAVESKY L, Jandakova E, Weinberger V, Minar L, et al
    Human endogenous retroviruses (HERVs) in breast cancer: altered expression pattern implicates divergent roles in carcinogenesis.
    Oncology. 2024 Feb 26. doi: 10.1159/000538021.
    PubMed     Abstract available


    January 2024
  6. HADAR M, Friger M, Ariad S, Koretz M, et al
    Stage I Breast Cancer in the Modern Era: A Retrospective Cohort Study of 328 Patients Diagnosed from 2002 to 2006 with a 14- year Median Follow-Up.
    Oncology. 2024 Jan 5. doi: 10.1159/000536119.
    PubMed     Abstract available


  7. JEON C, Kang SH, Kim SB, Paik NS, et al
    Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
    Oncology. 2024;102:465-475.
    PubMed     Abstract available


    December 2023
  8. CHIANG CH, Chang YC, Haw Y, Tan JY, et al
    The Effect of Exercise on Cardiotoxicity in Women with Breast Cancer Receiving Anthracycline-based chemotherapy: A Systematic Review and Meta-analysis.
    Oncology. 2023 Dec 15. doi: 10.1159/000535737.
    PubMed     Abstract available


    November 2023
  9. SARFRAZ H, Bari S, Whiting J, Sur M, et al
    A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience.
    Oncology. 2023 Nov 27:1-11. doi: 10.1159/000534953.
    PubMed     Abstract available


    September 2023
  10. HE Y, Chen Q, Zhu F, Liu C, et al
    Preoperative radiotherapy does not change the existing treatment paradigm in stage III breast cancer.
    Oncology. 2023 Sep 25. doi: 10.1159/000533858.
    PubMed     Abstract available


  11. ZHANG S, Yu X, Xiu Y, Qiao K, et al
    Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy.
    Oncology. 2023 Sep 5. doi: 10.1159/000533787.
    PubMed     Abstract available


    August 2023
  12. LANDRY CA, Blanter J, Ru M, Fasano J, et al
    Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
    Oncology. 2023 Aug 18. doi: 10.1159/000533420.
    PubMed     Abstract available


  13. KAR S, Niharika, Roy A, Patra SK, et al
    Overexpression of SOX2 Gene by Histone Modifications: SOX2 Enhances Human Prostate and Breast Cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation.
    Oncology. 2023 Aug 4:1-18. doi: 10.1159/000531195.
    PubMed     Abstract available


    July 2023
  14. YANG Y, Liu C, Zhuo ZL, Xie F, et al
    Germline mutations in 32 cancer susceptibility genes by Next-Generation Sequencing among breast cancer patients.
    Oncology. 2023 Jul 29. doi: 10.1159/000532095.
    PubMed     Abstract available


    February 2023
  15. DOGAN I, Kizildag I, Ozkurt S, Ibis K, et al
    Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.
    Oncology. 2023 Feb 21:1-8. doi: 10.1159/000529030.
    PubMed     Abstract available


    January 2023
  16. CANNELLA L, Perri F, Clemente O, von Arx C, et al
    The Complex Management of the Breast Angiosarcoma: A Retrospective Study.
    Oncology. 2023;101:234-239.
    PubMed     Abstract available


  17. SUZUKI Y, Kaneko H, Tamura Y, Okada A, et al
    Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy.
    Oncology. 2023;101:358-361.
    PubMed     Abstract available


  18. JORGENSEN JT
    The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
    Oncology. 2023;101:836-842.
    PubMed     Abstract available


  19. LIU L, Lewis N, Sun W, Whiting J, et al
    Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution Experience.
    Oncology. 2023;101:765-772.
    PubMed     Abstract available


    September 2022
  20. SAWA A, Bando H, Kamohara R, Takeuchi N, et al
    Absolute lymphocyte count (ALC) as an independent prognostic factor in metastatic breast cancer: a retrospective study.
    Oncology. 2022 Sep 13. pii: 000526963. doi: 10.1159/000526963.
    PubMed     Abstract available


    August 2022
  21. JAFRI M, Kristeleit H, Misra V, Baxter M, et al
    Eribulin treatment for patients with metastatic breast cancer: The United Kingdom experience - a multicenter retrospective study.
    Oncology. 2022 Aug 31. pii: 000526140. doi: 10.1159/000526140.
    PubMed     Abstract available


    July 2022
  22. CHOI HJ, Lee JH, Jung CS, Lee JE, et al
    Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Oncology. 2022 Jul 26. pii: 000526155. doi: 10.1159/000526155.
    PubMed     Abstract available


    April 2022
  23. NGUYEN V, Chen J, Lord R, Preda V, et al
    The Impact of Multidisciplinary Weight Management on Body Weight and Body Mass Composition in Women with Breast Cancer Post-Adjuvant Chemotherapy: A Retrospective Chart Review.
    Oncology. 2022 Apr 11. pii: 000524519. doi: 10.1159/000524519.
    PubMed     Abstract available


    March 2022
  24. SHIKDAR S, Hall S, Taylor B, de Los Angeles J, et al
    Evaluating the Response of Palbociclib on Progression Free Survival in Hormone Receptor Positive Metastatic Breast Cancer.
    Oncology. 2022 Mar 28. pii: 000524340. doi: 10.1159/000524340.
    PubMed     Abstract available


  25. CHAUHAN D, Geetika, Kumar S, Kumar R, et al
    Combined Interaction of Cellular and Extracellular Components Causes Genetic Cascade Activation in Breast Cancer Metastasis.
    Oncology. 2022 Mar 25. pii: 000524302. doi: 10.1159/000524302.
    PubMed     Abstract available


    February 2022
  26. FUJITA N, Fujita K, Kim SJ, Iguchi C, et al
    Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-up of Prognostic Study Using Propensity Score Matching.
    Oncology. 2022 Feb 3. pii: 000522384. doi: 10.1159/000522384.
    PubMed     Abstract available


    January 2022
  27. BILGILIER C, Fureder T, Kastner MT, Vass Z, et al
    Oral Abundance of Actinomyces spp. in Breast Cancer Patients.
    Oncology. 2022 Jan 20. pii: 000522070. doi: 10.1159/000522070.
    PubMed     Abstract available


    December 2021
  28. FABI A, Ciccarese M, Scagnoli S, Russillo M, et al
    Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?
    Oncology. 2021 Dec 7. pii: 000521252. doi: 10.1159/000521252.
    PubMed     Abstract available


  29. YAMAGUCHI K, Matsunuma R, Hayami R, Tsuneizumi M, et al
    Comparison of the Modified IHC4 Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer.
    Oncology. 2021 Dec 7. pii: 000521287. doi: 10.1159/000521287.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.